Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acrivastine
- Development stage
- Unknown
- Lead developer
- McNeil Products
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acrivastine is a second-generation H1-receptor antagonist antihistamine used for the symptomatic relief of seasonal allergic rhinitis, including symptoms such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. It functions by blocking the action of histamine at H1 receptors, thereby preventing symptoms associated with histamine release. Acrivastine is non-sedating and available in combination with pseudoephedrine.
- Brand names
- Benadryl Allergy Relief
- Other names
- acrivastina
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on acrivastine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acrivastine.